Detalhe da pesquisa
1.
The novel proautophagy anticancer drug ABTL0812 potentiates chemotherapy in adenocarcinoma and squamous nonsmall cell lung cancer.
Int J Cancer
; 147(4): 1163-1179, 2020 08 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-31943158
2.
Knowledge and awareness of biosimilars among oncology patients in Colorado, USA.
Future Oncol
; 15(22): 2577-2584, 2019 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-31339051
3.
Chemotherapy-induced neutropenia/febrile neutropenia prophylaxis with biosimilar filgrastim in solid tumors versus hematological malignancies: MONITOR-GCSF study.
Future Oncol
; 15(8): 897-907, 2019 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-30827127
4.
Outcomes of chemotherapy-induced (febrile) neutropenia prophylaxis with biosimilar filgrastim (Zarzio®) initiated "same-day" (< 24 h), "per-guidelines" (24-72 h), and "late" (> 72 h): findings from the MONITOR-GCSF study.
Support Care Cancer
; 27(6): 2301-2312, 2019 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-30343410
5.
Treatment patterns and outcomes in patients with non-small cell lung cancer receiving biosimilar filgrastim for prophylaxis of chemotherapy-induced/febrile neutropaenia: Results from the MONITOR-GCSF study.
Eur J Cancer Care (Engl)
; 28(4): e13034, 2019 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-30968997
6.
Safety Profile of Biosimilar Filgrastim (Zarzio/Zarxio): A Combined Analysis of Phase III Studies.
Oncologist
; 23(4): 403-409, 2018 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-29317553
7.
MONITOR-GCSF DLBCL subanalysis: Treatment patterns/outcomes with biosimilar filgrastim for chemotherapy-induced/febrile neutropenia prophylaxis.
Eur J Haematol
; 100(3): 241-246, 2018 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-29171913
8.
Fatigue- and health-related quality-of-life in anemic patients with lymphoma or multiple myeloma.
Support Care Cancer
; 26(4): 1253-1264, 2018 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-29116407
9.
Proposed biosimilar pegfilgrastim (LA-EP2006) compared with reference pegfilgrastim in Asian patients with breast cancer: an exploratory comparison from two Phase III trials.
Future Oncol
; 13(16): 1385-1393, 2017 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-28453299
10.
Over- and under-prophylaxis for chemotherapy-induced (febrile) neutropenia relative to evidence-based guidelines is associated with differences in outcomes: findings from the MONITOR-GCSF study.
Support Care Cancer
; 25(6): 1819-1828, 2017 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-28111718
11.
A Comparison of Proposed Biosimilar LA-EP2006 and Reference Pegfilgrastim for the Prevention of Neutropenia in Patients With Early-Stage Breast Cancer Receiving Myelosuppressive Adjuvant or Neoadjuvant Chemotherapy: Pegfilgrastim Randomized Oncology (Supportive Care) Trial to Evaluate Comparative Treatment (PROTECT-2), a Phase III, Randomized, Double-Blind Trial.
Oncologist
; 21(7): 789-94, 2016 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-27091420
12.
Treatment patterns and outcomes in the prophylaxis of chemotherapy-induced (febrile) neutropenia with biosimilar filgrastim (the MONITOR-GCSF study).
Support Care Cancer
; 24(2): 911-925, 2016 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-26306517
13.
Incidence of chemotherapy-induced nausea and vomiting with moderately emetogenic chemotherapy: ADVICE (Actual Data of Vomiting Incidence by Chemotherapy Evaluation) study.
Support Care Cancer
; 23(9): 2833-40, 2015 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-26081597
14.
Ipilimumab plus dacarbazine for previously untreated metastatic melanoma.
N Engl J Med
; 364(26): 2517-26, 2011 Jun 30.
Artigo
em Inglês
| MEDLINE | ID: mdl-21639810
15.
Outpatient management of pulmonary embolism in cancer: data on a prospective cohort of 138 consecutive patients.
J Natl Compr Canc Netw
; 12(3): 365-73, 2014 Mar 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-24616542
16.
Filgrastim biosimilar (EP2006): A review of 15 years' post-approval evidence.
Crit Rev Oncol Hematol
; 196: 104306, 2024 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-38401695
17.
Nuclear factor-kappa B and interleukin-6 related docetaxel resistance in castration-resistant prostate cancer.
Prostate
; 73(5): 512-21, 2013 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-23038213
18.
Usefulness of the PERFORM questionnaire to measure fatigue in cancer patients with anemia: a prospective, observational study.
Support Care Cancer
; 21(11): 3039-49, 2013 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-23793142
19.
Clinical experience with Zarzio® in Europe: what have we learned?
Support Care Cancer
; 21(10): 2925-32, 2013 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-23903799
20.
Epoetin alfa biosimilar (HX575): A review of 15 years' post-approval clinical experience.
Crit Rev Oncol Hematol
; 181: 103894, 2023 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-36481307